Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Biotechnology

Healthcare
$5.30 -2.45%

-$0.27 today

Market cap
$430.84M
Beta
0.51
P/E (TTM)
-5.6
EPS (TTM)
-$1.92
52W Low $7.61High $18.31

Volume 1.67M

Average 1.21M

PHAT Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Phathom Pharmaceuticals, Inc.NASDAQ: PHAT

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation dips below year-ago levels

Q1 FY2026 stock-based compensation of $5.53M fell 0.1% year over year, behind the +19.8% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 1.4% from the prior quarter. Over 3 fiscal years it compounded at +6.0% a year.

Context

  • Stock-based compensation amounted to 16.4% of revenue in FY2025, down 27.1 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -0.1% toward the trailing-twelve-month pace of +19.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$5.53M-1.4% QoQ
Last fiscal yearDec 2025
$28.72M+19.4% YoY
LTMMar 2026
$28.71M+19.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-0.1%——
1 year+19.4%——
3-year CAGR+6.0%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
28.72M USD
Year-over-year change
+19.4%
4-year CAGR
+14.3%

Stock-Based Compensation vs competitors

How PHAT compares with its peers on the latest reported figures

  • PHAT's LTM Mar 2026 stock-based compensation of $28.71M is the smallest of the 2 companies compared; the peer median is $51.03M.
  • Its year-over-year change of +19.8% is the lowest of 2, against a peer median of +21.9%.
  • Stock-based compensation amounts to 14.0% of revenue for PHAT, versus a peer median of 11.9%.
PHAT Competitors Peer median
Stock-Based Compensation for PHAT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ARDXArdelyx, Inc.LTM Mar 2026$51.03M +21.9%+65.8%11.9%
PHATPhathom Pharmaceuticals, Inc.LTM Mar 2026$28.71M +19.8%+6.0%14.0%
Peer median (excluding PHAT) $51.03M+21.9%+65.8%11.9%

Competitors are the stored peer set for PHAT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(143.88M)(197.72M)(201.59M)(334.33M)(221.25M)
Depreciation & Amortization521K620K575K795K633K
Deferred Income Tax00000
Stock-Based Compensation16.81M24.13M45.03M24.05M28.72M
Change in Working Capital(27.32M)5.44M(13.64M)(15.3M)(12.38M)
Accounts Receivables00(1.64M)(37.16M)(39.33M)
Inventory00(9.44M)(6.14M)(11.78M)
Accounts Payables(9.79M)8.68M6.41M34.94M34.1M
Other Working Capital(17.52M)(3.24M)(8.98M)(6.93M)4.63M
Other Non-Cash Items5.41M21M32.06M58.01M37.5M
Operating Cash Flow(148.46M)(146.53M)(137.58M)(266.77M)(166.78M)
Capital Expenditures(328K)(1.04M)(1.63M)(135K)(229K)
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow(328K)(1.04M)(1.63M)(135K)(229K)
Debt Repayment42.76M95.45M39.32M59.4M0
Common Stock Issued024.6M155.46M121.78M1.64M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities1.94M0172.8M1.6M(1.93M)
Financing Cash Flow44.71M120.04M367.58M182.77M(288K)
Effect of Forex Changes0(345K)000
Net Change in Cash(104.08M)(27.87M)228.37M(84.13M)(167.29M)
Free Cash Flow(148.79M)(147.57M)(139.21M)(266.91M)(166.78M)

Phathom Pharmaceuticals, Inc.

NASDAQ:PHAT

Intrinsic Alpha fair value

Locked

Current Price

$5.30

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.